Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Encompass Health Corporation (EHC) SEC Filings & Earnings Calls

EquiReason read 15 Encompass Health Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-08-13 — Encompass Health issued $100M additional 5.875% Senior Notes due 2034 at 98.75% of par, net proceeds ~$96.9M, used to repay revolving credit facility. Notes are additional issuance.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

EHCEncompass Health CorporationFollow EHC — free
Medical Care Facilities · Healthcare
—
Price chart with a free account
Market cap
12.2B
P/E TTM
20.2
Dividend yield
0.6%
52-week
—
Next earnings
28 Oct, in 4 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

13 Aug 20268-K · 8.01Encompass Health issued $100M additional 5.875% Senior Notes due 2034 at 98.75% of par, net proceeds ~$96.9M, used to repay revolving credit facility. Notes are additional issuance of existing $500M notes from May 2026.open

Figures in the filing · each found in the filing text

Additional Notes Principal · 2026-08-13$100M
Net Proceeds · 2026-08-13$97M
Coupon Rate · 2026-08-135.9%

Risks flagged

Increased debt leverage with $100M additional notes, though used to repay revolver.

“Issuance of $100M additional 5.875% senior notes due 2034.”
Read the original on SEC EDGAR ↗
7 Aug 202610-QCMS released final rule for IRF FY2027 with net 2.3% payment increase, while RCD expanded to Texas and California, affecting 33 Encompass IRFs.open

Figures in the filing · each found in the filing text

Medicare payment rate increase · FY20272.3%
IRFs subject to RCD · 2026-06-3033

Risks flagged

Medicare review choice demonstration expansion

“As of June 30, 2026, we have 33 of our IRFs (representing approximately 11.9% of our IRF Medicare claims) subject to RCD.” · word for word

Regulatory compliance cost

“RCD increases administrative burden and potential claim denials.”

Reimbursement risk

“Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors... could decrease our revenues.” · word for word
Read the original on SEC EDGAR ↗
5 Aug 20268-K · 2.02, 7.01Net Operating Revenue $1.60B (+10% y/y); Adjusted EBITDA $348M (+9% y/y); Adjusted EPS $1.55 (+11% y/y); Guidance: FY revenue guidance raised to $6.41-6.49B from $6.375-6.47B; adjusted EBITDA to $1.365-1.395B from $1.35-1.38B; adjusted EPSearningsopen

Figures in the filing · each found in the filing text

Net Operating Revenue · Q2-2026$1.60B+10% y/y
Adjusted EBITDA · Q2-2026$348M+9% y/y
Adjusted EPS · Q2-2026$1.55+11% y/y
Discharges · Q2-202668,895+6% y/y
Same-store Discharge Growth · Q2-20262.8%
Net Patient Revenue per Discharge · Q2-2026$22521.00+4% y/y
Cash Flows from Operating Activities · Q2-2026$283M+5% y/y
Adjusted Free Cash Flow · Q2-2026$177M-5% y/y

Guidance

FY revenue guidance raised to $6.41-6.49B from $6.375-6.47B; adjusted EBITDA to $1.365-1.395B from $1.35-1.38B; adjusted EPS to $6.02-6.25 from $5.89-6.11

Raised full-year guidance across all key metrics, reflecting strong volume growth and operating leverage.

Risks flagged

Labor cost pressure and reimbursement risk in healthcare.

“No explicit risk factors discussed, but industry-wide labor and reimbursement pressures are typical.”
Read the original on SEC EDGAR ↗
1 Jun 20268-K · 1.01, 2.03Encompass Health Corporation issued $500 million of 5.875% Senior Notes due 2034, increasing leverage via a material direct financial obligation.SEC ↗
15 May 20268-K · 1.01, 8.01Encompass Health issued $500M of 5.875% senior notes due 2034 via private placement, using proceeds to redeem $400M of 4.500% notes due 2028 and repay $100M of revolver. Refinancing extends maturity and locks in higher coupon.SEC ↗
1 May 202610-QMedicare payment rate increase 2.4; IRFs subject to RCD 33; Guidance: Proposed net Medicare payment rate increase of 2.4% effective October 1, 2026open

Figures in the filing · each found in the filing text

Medicare payment rate increase · IRF · FY20272.4%
IRFs subject to RCD · IRF · 2026-05-0133

Guidance

Proposed net Medicare payment rate increase of 2.4% effective October 1, 2026

CMS proposed a net 2.4% market basket increase for IRF Medicare payments for FY2027, which the company estimates will result in a net 2.4% increase to its Medicare payment rates.

Risks flagged

Medicare reimbursement dependency

“We are highly concentrated in our primary line of business, particularly with respect to Medicare regulations and reimbursement.” · word for word

Regulatory compliance burden from RCD expansion

“With the expansion to those two states, we expect 33 of our current inpatient rehabilitation hospitals (representing approximately 11.9% of our IRF Medicare claims) to be subject to RCD.” · word for word

Staffing shortages

“Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and potential union activity could increase staffing costs and adversely affect other financial and operating results and has done so in the past.” · word for word
Read the original on SEC EDGAR ↗
30 Apr 20268-K · 2.02, 7.01Released earnings results and quarterly financials; issued a Regulation FD disclosure (forward guidance or material update)earningsSEC ↗
7 Apr 2026DEF 14AAnnual proxy statement filed for 2026 shareholder meeting, detailing executive compensation, governance, and 2025 performance.open

Figures in the filing · each found in the filing text

Adjusted EBITDA · FY2025$1.27B
Net income · FY2025$759M
Number of hospitals · 2026-03-10174
New beds added · FY2025340
Expanded beds · FY2025177
Nurse turnover reduction · FY2025$20.00
CEO pay ratio · FY2025$203.00
5-year cumulative TSR · FY2025$170.02

Risks flagged

Regulatory and reimbursement risk

“Healthcare is a highly regulated industry. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments.” · word for word

Workforce composition risk

“Approximately 43% of our workforce consists of employees working less than full-time, which is a common employment arrangement in the healthcare services sector.” · word for word
Read the original on SEC EDGAR ↗
10 Mar 20268-K · 1.01, 1.02, 2.03Encompass Health terminated its 2022 credit agreement and entered a new credit agreement with Truist Bank as agent, with collateral and guarantee agreement.SEC ↗
26 Feb 202610-KNet operating revenues $3.69B; Net income $759M; Operating cash flow $1.18B; Guidance: Capex guidance for 2026: $920M to $995M, up from $736M in 2025open

Figures in the filing · each found in the filing text

Net operating revenues · FY2025$3.69B
Net income · FY2025$759M
Operating cash flow · FY2025$1.18B
Adjusted EBITDA · FY2025$1.27B
Capital expenditures · FY2025$736M
Number of hospitals · FY2025173
Long-term debt · FY2025$2.07B
Free cash flow · FY2025$441M

Guidance

Capex guidance for 2026: $920M to $995M, up from $736M in 2025

Capex guidance raised significantly, indicating management confidence in demand and expansion.

Risks flagged

Payer mix shift to lower reimbursement

“We have in recent years experienced, and in the future may, experience shifts in our payor mix or the acuity of our patients that could adversely affect our reimbursement, Net operating revenues, and profitability.” · word for word

Convener influence reducing patient volumes

“Conveners may influence referral source decisions on which post-acute setting to recommend, as well as how long to remain in a particular setting.” · word for word

Medicare/Medicaid reimbursement changes

“The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, in the United States may significantly affect our business and results of operations.” · word for word
Read the original on SEC EDGAR ↗
5 Feb 20268-K · 2.02, 7.01Net operating revenue $1.54B (+10% y/y); Adjusted earnings per share $1.46 (+25% y/y); Adjusted EBITDA $336M (+16% y/y); Guidance: 2026 revenue guidance $6,365-$6,465M, adjusted EBITDA $1,340-$1,380Mearningsopen

Figures in the filing · each found in the filing text

Net operating revenue · Q4-2025$1.54B+10% y/y
Adjusted earnings per share · Q4-2025$1.46+25% y/y
Adjusted EBITDA · Q4-2025$336M+16% y/y
Discharges · Q4-202567,238+5% y/y
Net patient revenue per discharge · Q4-2025$22273.00+4% y/y
Adjusted free cash flow · Q4-2025$235M+24% y/y

Guidance

2026 revenue guidance $6,365-$6,465M, adjusted EBITDA $1,340-$1,380M

2026 guidance implies continued strong growth with revenue up ~10% and adjusted EBITDA up ~10% at midpoint.

Risks flagged

Dependence on aging population trends and regulatory reimbursement environment.

“need for the services we provide continues to grow as the U.S. population ages” · word for word
Read the original on SEC EDGAR ↗
2 Feb 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportSEC ↗
1 Dec 20258-K · 7.01Encompass Health reiterates full-year 2025 guidance: net operating revenue $5,905M-$5,955M, adjusted EBITDA $1,235M-$1,255M, adjusted EPS $5.22-$5.37.open

Figures in the filing · each found in the filing text

Net operating revenue · FY2025$5.91B
Adjusted EBITDA · FY2025$1.24B
Adjusted EPS · FY2025$5.22

Guidance

FY2025 net operating revenue $5,905M-$5,955M; adjusted EBITDA $1,235M-$1,255M; adjusted EPS $5.22-$5.37

Full-year 2025 guidance reaffirmed with no changes; stable outlook.

Risks flagged

Guidance unchanged; no new risks disclosed beyond standard forward-looking statements.

“Standard risk factors listed in forward-looking statements; no specific new risks.”
Read the original on SEC EDGAR ↗
31 Oct 202510-QEncompass Health reported 9.4% revenue growth in Q3 2025, driven by volume and pricing, with continued expansion.earningsopen

Guidance

Management optimistic about long-term demand from aging demographics; no specific numeric guidance provided.

Risks flagged

Medicare reimbursement risk

“Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors... could decrease our revenues and adversely affect other operating results.” · word for word

Staffing shortage risk

“Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages... could increase staffing costs and adversely affect other financial and operating results” · word for word
Read the original on SEC EDGAR ↗
29 Oct 20258-K · 2.02, 7.01Net operating revenue $1.48B (+9% y/y); Adjusted earnings per share $1.23 (+19% y/y); Adjusted EBITDA $300M (+11% y/y); Guidance: Revenue guidance raised to $5,905-$5,955M (from $5,880-$5,980); EBITDA to $1,235-$1,255M (from $1,220-$1,250);earningsopen

Figures in the filing · each found in the filing text

Net operating revenue · Q3-2025$1.48B+9% y/y
Adjusted earnings per share · Q3-2025$1.23+19% y/y
Adjusted EBITDA · Q3-2025$300M+11% y/y
Discharges · Q3-202565,839+5% y/y
Same-store discharge growth · Q3-20252.9%
Net patient revenue per discharge · Q3-2025$21679.00+3% y/y
Cash flows provided by operating activities · Q3-2025$271M+1% y/y
Adjusted free cash flow · Q3-2025$174M-8% y/y

Guidance

Revenue guidance raised to $5,905-$5,955M (from $5,880-$5,980); EBITDA to $1,235-$1,255M (from $1,220-$1,250); EPS to $5.22-$5.37 (from $5.12-$5.34)

Full-year guidance raised across all metrics; strong volume growth and margin expansion

Risks flagged

Adjusted free cash flow declined 8.2% YoY despite revenue growth

“Adjusted free cash flow $174.2M vs $189.7M, -8.2%”
Read the original on SEC EDGAR ↗

Encompass Health Corporation — questions

What did Encompass Health Corporation file recently?
15 SEC filings in the last 12 months. Latest: 8-K on 2026-08-13 — Encompass Health issued $100M additional 5.875% Senior Notes due 2034 at 98.75% of par, net proceeds ~$96.9M, used to repay revolving credit facility. Notes are additional issuance of existing $500M notes from May 2026.

Every figure on this page comes from Encompass Health Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.